Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast
A phase 3 trial of Petosemtamab, Cetuximab, Bevacizumab in colorectal cancer, run by Genmab, now recruiting.
Overview
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) is a phase 3 interventional study registered as NCT07775287 by Genmab, with 600 participants planned, started 2026-09-15 and due to reach its primary completion in 2029-03-30. Interventions recorded: Petosemtamab, Cetuximab, Bevacizumab, 5-FU, Leucovorin (Calcium Folinate). Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialBOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Shares Leucovorin (folinic acid), FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Colorectal cancer.
- TrialStudy of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta
Shares Petosemtamab, Genmab, Cetuximab, Colorectal cancer.
- TrialA Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Shares Leucovorin (folinic acid), Cetuximab, Bevacizumab, Colorectal cancer.
- TrialA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Bevacizumab, Colorectal cancer.
- TrialStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese
Shares Leucovorin (folinic acid), Fluorouracil (5-FU), Bevacizumab, Colorectal cancer.
- TrialA Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Cetuximab, Bevacizumab, Colorectal cancer.
- TrialA Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P
Shares Petosemtamab, Genmab.
- TrialA Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Bevacizumab, Colorectal cancer.